Literature DB >> 6125176

Effects of beta-adrenoceptor antagonists on central haemodynamics in essential hypertension.

H Tsukiyama, K Otsuka, K Higuma.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125176      PMCID: PMC1402149          DOI: 10.1111/j.1365-2125.1982.tb01924.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

1.  Experience with pindolol, a betareceptor blocker, in the treatment of hypertension.

Authors:  J H Atterhög; H Dunér; B Pernow
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

2.  Effect of thoracic blood volume changes on steady state cardiac output.

Authors:  W Mitzner; H Goldberg; S Lichtenstein
Journal:  Circ Res       Date:  1976-04       Impact factor: 17.367

3.  Possible role of a beta-adrenoceptor in the regulation of noradrenaline release by nerve stimulation through a positive feed-back mechanism.

Authors:  E Adler-Graschinsky; S Z Langer
Journal:  Br J Pharmacol       Date:  1975-01       Impact factor: 8.739

4.  Increased pulmonary vascular resistance with systemic hypertension. Effect of minoxidil and other antihypertensive agents.

Authors:  J M Atkins; H C Mitchell; W A Pettinger
Journal:  Am J Cardiol       Date:  1977-05-26       Impact factor: 2.778

5.  Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations.

Authors:  R C Tarazi; H P Dustan
Journal:  Am J Cardiol       Date:  1972-05       Impact factor: 2.778

Review 6.  A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.

Authors:  R T Brittain; G P Levy
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

7.  Direct effect of beta-adrenergic stimulation on renin release by the rat kidney slice in vitro.

Authors:  M H Weinberger; W Aoi; D P Henry
Journal:  Circ Res       Date:  1975-09       Impact factor: 17.367

8.  Total effective compliance of the vascular bed in essential hypertension.

Authors:  G M London; M E Safar; Y A Weiss; C A Simon
Journal:  Am Heart J       Date:  1978-03       Impact factor: 4.749

9.  USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION.

Authors:  B N PRICHARD; P M GILLAM
Journal:  Br Med J       Date:  1964-09-19

10.  Non-invasive estimation of the human pulmonary blood volume with gamma camera and RI-angiocardiography.

Authors:  K Goto; A Hirano; S Hirakawa
Journal:  Jpn Circ J       Date:  1981-01
  10 in total
  6 in total

1.  Differential cardiovascular effects of propranolol, atenolol, and pindolol measured by impedance cardiography.

Authors:  S H Thomas; R C Cooper; M Ekwuru; S Fletcher; J Gilbody; T S Husseyin; M Ishaque; R Jagathesan; G Reddy; S E Smith
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Haemodynamic effects of new beta-blockers with vasodilatory properties in essential hypertension.

Authors:  H Tsukiyama; K Otsuka; M Horii
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.

Authors:  G T Tucker; N D Bax; M S Lennard; S Al-Asady; H S Bharaj; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

4.  Comparison of the renal effects of dilevalol and carteolol in patients with mild to moderate essential hypertension.

Authors:  T Baba; S Murabayashi; T Tomiyama; K Takebe
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

6.  The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension.

Authors:  Regina Pawlak-Chomicka; Tomasz Krauze; Pawel Uruski; Jaroslaw Piskorski; Andrzej Wykretowicz; Andrzej Tykarski; Przemyslaw Guzik
Journal:  Cardiol Res Pract       Date:  2022-03-31       Impact factor: 1.866

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.